Thus, we need to further investigate whether CPO-induced CD133 degradation affects EGR2 and apolipoprotein B expression levels, to overcome nonalcoholic fatty liver disease. The gene discussed is CPO; the disease is metabolic dysfunction-associated steatotic liver disease.